The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences.
The cardinal clinical manifestations of major depression with melancholic features include sustained anxiety and dread for the future as well as evidence of physiological hyperarousal (e.g., sustained hyperactivity of the two principal effectors of the stress response, the corticotropin-releasing-hormone, or CRH, system, and the locus ceruleus-norepinephrine, or LC-NE, system). Sustained stress system activation in melancholic depression is thought to confer both behavioral arousal as well as the hypercortisolism, sympathetic nervous system activation, and inhibition of programs for growth and reproduction that consistently occur in this disorder. Data also suggest that activation of the CRH and LC systems in melancholia are involved in the long-term medical consequences of depression such as premature coronary artery disease and osteoporosis, the two-three-fold preponderance of females in the incidence of major depression, and the mechanism of action of antidepressant drugs. In addition, recent data reveal important bidirectional interactions between stress-system hormonal factors in depression and neural substrates implicated in many discrete behavioral alterations in depression (e.g., the medial prefrontal cortex, important in shifting affect based on internal and external cues, the mesolimbic dopaminergic reward system, and the amygdala fear system). We have also advanced data indicating that the hypersomnia, hyperphagia, lethargy, fatigue, and relative apathy of the syndrome of atypical depression are associated with concomitant hypofunctioning of the CRH and LC-NE systems. These data indicate the need for an entirely different therapeutic strategy than that used in melancholia for the treatment of atypical depression, and they suggest that this subtype of major depression will be associated with its own unique repertoire of long-term medical consequences.
Gold
P W
PW
National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1284, USA.
Chrousos
G P
GP
D003346:Corticotropin-Releasing Hormone / Q000502:physiology*; D003863:Depression / Q000503:physiopathology*; D003866:Depressive Disorder / Q000503:physiopathology*; D006801:Humans; D008125:Locus Coeruleus / Q000503:physiopathology*; D009638:Norepinephrine / Q000502:physiology*
D003346:Corticotropin-Releasing Hormone; D009638:Norepinephrine